Bevacizumab – Anti-Angiogenic Monoclonal Antibody
Bevacizumab is a recombinant humanized monoclonal antibody used as a targeted cancer therapy. It works by inhibiting vascular endothelial growth factor (VEGF), a protein responsible for the formation of new blood vessels (angiogenesis). By blocking VEGF, Bevacizumab helps restrict the blood supply required for tumor growth and progression.
Mechanism of Action
Bevacizumab binds specifically to VEGF and prevents it from interacting with its receptors on the surface of endothelial cells. This action:
-
Inhibits the formation of new blood vessels that supply tumors
-
Slows tumor growth and spread
-
Enhances the effectiveness of chemotherapy when used in combination
This targeted approach helps control cancer progression while minimizing effects on normal cells.
Indications & Clinical Use
Bevacizumab is approved and widely used in the treatment of several cancers, including:
-
Colorectal cancer (metastatic)
-
Non-small cell lung cancer (NSCLC)
-
Ovarian cancer
-
Cervical cancer
-
Renal cell carcinoma (kidney cancer)
-
Glioblastoma (brain tumor)
It is commonly administered in combination with standard chemotherapy regimens based on the cancer type and stage.
Administration
Bevacizumab is administered by a healthcare professional via intravenous (IV) infusion. Dosage and treatment intervals depend on the specific indication and patient condition. Patients are closely monitored during therapy for safety and treatment response.
Key Benefits
-
Targets tumor blood supply
-
Proven efficacy across multiple cancer types
-
Improves outcomes when combined with chemotherapy
-
Well-established clinical safety profile
